Introduction

This special issue on cochlear implants is dedicated posthumously to William F. House, M.D., the Father of Neurotology. Dr. House initiated the first national clinical trial on cochlear implants. I was privileged to be one of his fellows and to be included in this first Co-Investigator group and implanted our first patient in 1979. This led to our involvement as an FDA Consultant and later FDA ENT Devices Panel member. This clinical trialled to the first ever FDA approval for cochlear implants and opened the door for unprecedented advances in the treatment of deafness and hearing loss. Dr. Ingeborg Hochmair was working in parallel with Dr. House from the very earliest days of cochlear implantation. I was invited to Vienna by her to observe some of her excellent results and spent an exciting week at the beginning of my career. Professor Hochmair is President and CEO of MED-EL Corporation. She has continued to improve cochlear implant and electrode design and has incorporated the latest coding strategies. Dr. Blake Wilson is a master at developing new coding strategies as they apply to cochlear implants and determining how to assess them. He has been continuously supported by the National Institutes of Health. He has kept his invaluable research in the public sector so as to have it available to anyone. Dr. Fred Linthicum was one of my fellowship mentors and one of the preeminent temporal bone histopathologists in the world. Some of the temporal bones from my earliest cochlear implant patients are among his collection. His studies have provided insight into what is stimulated by a cochlear implant (the ganglion cell bodies) and the changes that are the result of the insertion and presence of the implant. Dr. David Pisoni has been my colleague in the DeVault Otologic Laboratories from the beginnings of our NIDCD